［1］国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版). 中华神经外科杂志, 2019, 35 (3): 217-241.

［2］蒋朱明, 詹思延, 贾晓巍, 等. 制定/修订《临床诊疗指南》的基本方法及程序. 中华医学杂志, 2016, 96 (4): 250-253.

［3］《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南 (2015). 中华医学杂志, 2016, 96 (7): 485-509.

［4］BRAT D J, ALDAPE K, COLMAN H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ”. Acta Neuropathol, 2018, 136(5): 805-810.

［5］BRAT D J, ALDAPE K, COLMAN H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol, 2020,139 (3): 603-608.

［6］ELLISON D W, ALDAPE K D, CAPPER D, et al. cIMPACTNOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol, 2020, doi: 10.1111/bpa. 12866.

［7］ELLISON D W, HAWKINS C, JONES D T W, et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF (V600E)mutation. Acta Neuropathol, 2019, 137 (4): 683-687.

［8］JIANG T, MAO Y, MA W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas.Cancer Lett, 2016, 375 (2): 263-273.

［9］LIANG S L, FAN X, ZHAO M, et al. Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy. Cancer Med, 2019, 8 (10): 4527-4535.

［10］LOUIS D N, ALDAPE K, BRAT D J, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to cns tumor taxonomy. Acta Neuropathol, 2017, 133 (1): 1-3.

［11］LOUIS D N, ELLISON D W, BRAT D J, et al. cIMPACTNOW: a practical summary of diagnostic points from round 1 updates. Brain Pathol, 2019, 29 (4): 469-472.

［12］LOUIS D N, GIANNINI C, CAPPER D, et al. cIMPACTNOW update 2: diagnostic clarifications for diffuse midline glioma, H3K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol,2018, 135 (4): 639-642.

［13］LOUIS D N, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol, 2016, 131 (6): 803-820.

［14］LOUIS D N, WESSELING P, ALDAPE K, et al. cIMPACTNOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol, 2020,30 (4): 844-856.

［15］LOUIS D N, WESSELING P, PAULUS W, et al. cIMPACTNOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol, 2018,135 (3): 481-484.

［16］Oxford Centre for Evidence-Based Medicine (OCEBM).Oxford Centre for Evidence-based Medicine–Levels of Evidence (March 2009). [2020-01-01]. https://www. cebm.net/2009/06/oxford-centre-evidence-based-medicine-levelsevidence-march-2009.